NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, ...

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

BAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $4.03 billion. On a per-share basis, the Bagsvaerd, Denmark-based company said ...

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities ...

Novo Nordisk also released its second quarter results this week, boasting profit of more than $4 billion. Per-share earnings ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Eli Lilly and Company LLY will report its second-quarter earnings on Aug. 7, before market open. The Zacks Consensus Estimate ...

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a Sell.